Alberta source: bounded use
Provincial Giant Cell Arteritis Primary Care Clinical Pathway supplies a Canadian implementation example for this summary. It must not be presented as the rule outside Alberta.
sources for this section:AHS GCA pathway
Source-attributed clinical priorities
- Treat new visual symptoms, jaw or tongue claudication, ischemic neurologic symptoms or high clinical suspicion as an emergency.
- Start appropriate glucocorticoid treatment without delaying for confirmatory testing when vision is threatened.
- Coordinate temporal-artery imaging or biopsy and longitudinal monitoring through the local urgent specialty pathway.
- Visual ischemic symptoms require same-day specialist coordination even if inflammatory markers are normal.
sources for this section:AHS GCA pathway
Practical assessment and management workflow
1
Ask about new headache, scalp tenderness, jaw or tongue claudication, constitutional symptoms and polymyalgia features.
2
Examine vision, pupils, temporal arteries, pulses and neurologic status and obtain inflammatory and baseline safety tests.
3
Start treatment immediately when clinical suspicion threatens vision, then arrange confirmatory ultrasound or biopsy.
4
Monitor visual and vascular symptoms, inflammatory response, relapse and glucocorticoid toxicity longitudinally.
sources for this section:AHS GCA pathway
Safety, red flags and urgent escalation
- Do not postpone glucocorticoids for imaging or biopsy when vision is at risk.
- Escalate transient or permanent visual loss, diplopia, stroke symptoms or limb ischemia immediately.
- Assess for large-vessel aortitis when symptoms or examination indicate it.
sources for this section:AHS GCA pathway
Confirm the local pathway before acting
Alberta is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.
sources for this section:AHS GCA pathway
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:AHS GCA pathway
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Alberta Health ServicesProvincial Giant Cell Arteritis Primary Care Clinical PathwayUpdated 2025-05 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.